Share this article
Share this article
NEW YORK, June 3, 2021 /PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of
Verrica Pharmaceuticals Inc. ( Verrica or the Company ) (NASDAQ: VRCA). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Verrica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On June 1, 2021, Verrica issued a press release announcing that the U.S. Food and Drug Administration ( FDA ) extended the review period by three months for its New Drug Application ( NDA ) of VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious viral skin disease. Specifically, the press release indicated that [o]n May 26, the company was informed by the FDA that the information submitted has been designated a major amendment, and therefore, the FDA will take a
NEW YORK, June 3, 2021 /PRNewswire/ Â Pomerantz LLP is investigating claims on behalf of investors of
 Verrica Pharmaceuticals Inc. ( Verrica or the Company ) (NASDAQ: VRCA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.
The investigation concerns whether Verrica and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.Â
- Advertisement -
On June 1, 2021, Verrica issued a press release announcing that the U.S. Food and Drug Administration ( FDA ) extended the review period by three months for its New Drug Application ( NDA ) of VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious viral skin disease. Â Specifically, the press release indicated that [o]n May 26, the company was informed by the FDA that the information submitted has been designated a major amendment, and therefore, the FDA will take
FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
PDUFA date of
DUBLIN, Ireland, and
Boston MA,
June 3, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the U.S. Food and Drug Administration (“FDA”) has granted Priority Review for Amryt’s New Drug Application (“NDA”) for Oleogel-S10 for the treatment of Epidermolysis Bullosa (“EB”). Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment.